J&J's Zytiga gets OK in Scotland; Novartis touts long-term Cosentyx results; Amgen's Prolia scores in head-to-head osteoporosis trial;

@FiercePharma: Study: Elephants rarely get cancer--and that could boost human oncology research. FierceAnimalHealth story | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Sanofi's Kansas City, MO, plant back on the block as its August 2016 closing looms. Story | Follow @EricPFierce

@CarlyHFierce: Backlash rages on over Purdue's pediatric OxyContin approval. Story | Follow @CarlyHFierce

> Johnson & Johnson's ($JNJ) prostate cancer treatment Zytiga won approval from the Scottish Medicines Consortium, which means it can be routinely used in that country; the drug still lacks routine approval in England and Wales. Release

> Novartis ($NVS) unveiled new data showing that a majority of psoriasis patients using Cosentyx were able to maintain clear or almost clear skin for three years. Release

> Amgen's ($AMGN) Prolia delivered larger gains in bone-mineral density than the IV bisphosphonate drug zoledronic acid in postmenopausal women with osteoporosis who'd previously been treated with bisphosphonates. Release

> New U.S. drug approvals promise better second-half results for Indian drugmakers, analysts said, compared with the first six months of this year. Report

Medical Device News

@FierceMedDev: ICYMI Friday: Procyrion raises $10M to get minimally invasive mini heart pump in the clinic. Article | Follow @FierceMedDev

@VarunSaxena2: ICYMI last week from #AdvaMed15: CMS has 30 people to evaluate 30,000 diagnostic tests, but more FDA oversight is likely. More | Follow @VarunSaxena2

@EmilyWFierce: The latest from Advera Health Analytics on Alzheimer's drug safety. ICYMI from FiercePharma | Follow @EmilyWFierce

> NuVasive gets FDA blessing for spinal cord surgical device. Report

> Clinicians criticize Baxter for suspending comparative drug/device heart failure trial. More

> Neurosurgeons hope brain implants can be used to treat array of mental disorders. Article

Biotech News

@FierceBiotech: Lilly upgrades its NYC research hub, adding 50 jobs in an immuno-oncology push. News | Follow @FierceBiotech

@JohnCFierce: How many big swings and misses does John Lechleiter get at $LLY? | Follow @JohnCFierce

@DamianFierce: Tired of writing about $LLY today so here's a hypoglycemia deal you can read about yourself. Press release | Follow @DamianFierce

> Novartis buys a bigger stake in Gamida, stopping short of a $600M plunge. Report

> Lilly pulls the plug on a would-be blockbuster in its latest pipeline peril. Story

> Voyager braves turbulent market waters with an $86M gene therapy IPO. Article

Animal Health News

> Study: Elephants rarely get cancer--and that could boost human oncology research. More

> Ceva urges mass vaccination against bird flu at global animal-health gathering. Story

> FDA seeks comments on potential scheduling change for ketamine. Item

> California sets strictest U.S. standards for antibiotics use in livestock. Article

> CalTech team creates one-time contraceptive vaccine for feral animals. Report

Biotech IT News

> NIH gives UCSF $10M to build mobile data collection platform. News

> GSK finds 21M mentions of its drugs in trawl of social media. Report

> ResearchKit-enabled project sets out to track real-world effectiveness of hep C drugs. Story

> UBiome taps Apple ecosystem to broaden microbiome data-gathering drive. Article

> Is Google a competitor or partner to Big Pharma? Roche's CEO doesn't know, yet. More

Pharma Marketing News

> Baxalta joins biosim makers eyeing a piece of AbbVie's Humira. More

> Biogen's top commercial exec leaves amid Tecfidera sales trouble. Report

> Roche leads the pack at ECTRIMS with standout data on new MS drug. Item

> Bill seeks to add nurse practitioners, PAs to Sunshine Act reporting. Story

> Pharma's digital desires thwarted by clunky organizations, lack of skilled employees. Article

And Finally... Merck KGaA says it's betting its cancer pipeline can rescue it from a decline in sales of its top-selling multiple sclerosis drug Rebif. Report

Suggested Articles

Even as it gears up for phase 3 testing, Moderna has started commercial COVID-19 vaccine manufacturing, its CEO said.

Fitness guru and heart attack survivor Bob Harper is back again in AstraZeneca’s awareness effort to offer support and education to fellow survivors.

Taxpayers spent nearly $100 million to save remdesivir from the "scrapheap," a lawmaker wrote, and are being repaid with "price gouging."